Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Apr 1;29(10):1349-55.
doi: 10.1200/JCO.2010.31.1811. Epub 2011 Feb 14.

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712

Jennifer A Woyach  1 , Amy S Ruppert, Nyla A Heerema, Bercedis L Peterson, John G Gribben, Vicki A Morrison, Kanti R Rai, Richard A Larson, John C Byrd
Affiliations
Randomized Controlled Trial

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712

Jennifer A Woyach et al. J Clin Oncol. .

Abstract

Purpose: The addition of rituximab to fludarabine-based regimens in chronic lymphocytic leukemia (CLL) has been shown to produce high response rates with extended remissions. The long-term follow-up of these regimens with respect to progression, survival, risk of secondary leukemia, and impact of genomic risk factors has been limited.

Methods: We report the long-term follow-up of the chemoimmunotherapy trial CALGB 9712 from the Cancer and Leukemia Group B, for which treatment regimen was previously reported, to examine end points of progression-free survival (PFS), overall survival (OS), impact of genomic features, and risk of therapy-related myeloid neoplasm (t-MN).

Results: A total of 104 patients were enrolled on this study and now have a median follow-up of 117 months (range, 66 to 131 months). The median OS was 85 months, and 71% of patients were alive at 5 years. The median PFS was 42 months, and 27% were progression free at 5 years. An estimated 13% remained free of progression at almost 10 years of follow-up. Multivariable models of PFS and OS showed that immunoglobulin heavy chain variable region mutational status was significant for both, whereas cytogenetic abnormalities were significant only for OS. No patient developed t-MN before relapse.

Conclusion: Long-term follow-up of CALGB 9712 demonstrates extended OS and PFS with fludarabine plus rituximab. Patients treated with fludarabine plus rituximab administered concurrently or sequentially have a low risk of t-MN. These long-term data support fludarabine plus rituximab as one acceptable first-line treatment for symptomatic patients with CLL.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
CONSORT diagram. FR, rituximab with fludarabine.
Fig 2.
Fig 2.
Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS) for all 104 patients on Cancer and Leukemia Group B study CALGB 9712.
Fig 3.
Fig 3.
Kaplan-Meier estimates of overall survival after progression.
Fig 4.
Fig 4.
(A) Kaplan-Meier estimates of progression-free survival (PFS) in patients with mutated immunoglobulin heavy chain variable region (IgVH) versus unmutated IgVH. (B) Kaplan-Meier estimates of overall survival (OS) in patients with mutated IgVH versus unmutated IgVH. (C) Kaplan-Meier estimates of PFS in patients with del(17p13.1)/del(11q22.3) versus those without these poor-risk abnormalities. (D) Kaplan-Meier estimates of OS in patients with del(17p13.1)/del(11q22.3) versus those without these poor-risk abnormalities.
See this image and copyright information in PMC

Comment in

References

    1. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750–1757. - PubMed
    1. Johnson S, Smith AG, Löffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia: The French Cooperative Group on CLL. Lancet. 1996;347:1432–1438. - PubMed
    1. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319–2325. - PubMed
    1. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114:3382–3391. - PubMed
    1. Rai K, Peterson BL, Appelbaum FR, et al. Long-term survival analysis of the north american intergroup study c9011 comparing fludarabine and chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Blood. 2009;114:536. abstr 536.

Publication types

MeSH terms